Breaking News

FDA Extends CRADA with CluePoints

Aims to further explore a data-driven approach to quality oversight in clinical trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

The FDA has extended its Cooperative Research and Development Agreement (CRADA) with CluePoints to October 2021 to include additional research focused on “moderators of treatment effect” and real-world evidence. Additional analyses based on these moderators of treatment effect will include geographic region, country and supervising Contract Research Organizations (CROs).   The FDA also plans to conduct statistical tests provided by CluePoints such as Key Risk Indicators (KRIs) that will supple...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters